Public Policy – Not The Economy – Must Be Biotech Sector’s Focus, BIO CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The capital crisis will pass, Greenwood says, but the need to engage on public policy will remain paramount. A sign of a mature industry?
You may also be interested in...
Follow-on Biologics Savings Lower In Administration’s Budget Proposal
FOB pathway would create only $6.35 billion in savings, according to the budget, down from the $9.24 billion projected in February.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.